Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGE-217 Relapse Prevention in MDD
NCT04007367Phase 3Terminated
- Sponsor
- Biogen
- Start
- Aug 2019
- Primary completion
- Jan 2020
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of zuranolone in major depressive disorder (MDD), sponsored by Biogen. Started Aug 2019; status: terminated.
02
Drugs
zuranolone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04007367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007367.